Advanced Filters
noise

congenital-afibrinogenemia Clinical Trials

A listing of congenital-afibrinogenemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 5 clinical trials
R Ryan Metcalf, MD

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a randomized study design to reduce risk of bias. Alerts will be visible to the experimental ordering provider group, while they will …

18 - 100 years of age Both Phase N/A
M Melissa Cushing, MD

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinogen (the main substrate of a blood clot), early bleeding can be …

18 - 100 years of age Both Phase 4
E Ekaterina Baryshnikova, PhD

Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness

Fibrinogen concentrate is produced by different manufacturers using different purification technologies. The products available in Italy are three: RIASTAP (CSL Behring), FIBRYGA (Octapharma), and FIBRICLOTTE (LFB). RIASTAP and FIBRYGA are sold in 1-gram vials, and FIBRICLOTTE - in 1.5 grams vials. A recent in vitro study assessed how these products …

18 - 100 years of age Both Phase 2

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Open-label, Uncontrolled, Multicenter Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

- 100 years of age Both Phase N/A
L Laurent Servais, MD, PhD

Baby Detect : Genomic Newborn Screening

Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of …

- 28 years of age Both Phase N/A

Rewrite in simple language using AI